Skip to content

Author

J. Zugazagoitia

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Context-dependent value of HLA class I diversity in advanced non-small cell lung cancer treated with immune checkpoint blockade

Immune checkpoint inhibitors (ICI), alone or in combination with chemotherapy, are the standard first-line treatment for advanced non–small cell lung cancer (NSCLC) without actionable oncogenic drivers. Programmed death-ligand 1 (PD-L1) expression and tumor mutational burden (TMB) are routinely used biomarkers, yet...

J. Ramos-Paradas, N. Carrizo, Eva Álvarez et al. · 0 citations
Open access Sep 2026

Tumor cell-expressed OX40L enhances the efficacy of PD-1 axis blockade in non-small cell lung cancer

Abstract Background Immune checkpoint inhibitors have transformed non-small cell lung cancer (NSCLC) treatment. Understanding the tumor-immune interactions that dictate sensitivity to PD-1 blockade is essential for improving outcomes and optimizing immunotherapy personalization. Methods We performed compartment-specifi...

C. Fernández-Luna, J. Baena, A. Calles et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.